ABEO Stock Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
Notes are coming soon
Abeona Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.65|
|52 Week High||US$9.36|
|52 Week Low||US$2.34|
|1 Month Change||-13.96%|
|3 Month Change||-42.27%|
|1 Year Change||-54.72%|
|3 Year Change||-95.12%|
|5 Year Change||-99.30%|
|Change since IPO||-100.00%|
Recent News & Updates
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash WiselyMar 02
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing MoneyAug 17
Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its DebtApr 28
Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)Feb 21
How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?Jan 19
What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?Dec 15
|ABEO||US Biotechs||US Market|
Return vs Industry: ABEO underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ABEO underperformed the US Market which returned -9.2% over the past year.
|ABEO Average Weekly Movement||10.9%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ABEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ABEO's weekly volatility (11%) has been stable over the past year.
About the Company
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders.
Abeona Therapeutics Inc. Fundamentals Summary
|ABEO fundamental statistics|
Is ABEO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABEO income statement (TTM)|
|Cost of Revenue||US$1.44m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-5.18|
|Net Profit Margin||-2,048.67%|
How did ABEO perform over the long term?See historical performance and comparison